NERV · NASDAQ · Biotechnology

Minerva Neurosciences (NERV)

Develops roluperidone for negative symptoms of schizophrenia through a confirmatory Phase 3 trial.

$3.62
vs last close−0.19 (−4.99%)
  1. What Makes Minerva Neurosciences (NERV) a New Buy Stock

    Zacks Investment Research